When was Bonum Therapeutics founded?

Bonum Therapeutics was founded in 2021 and raised its 1st funding round 1 year after it was founded.

Where is Bonum Therapeutics located?

Bonum Therapeutics is headquartered in Seattle, United States.

Who is the current CEO of Bonum Therapeutics?

John Mulligan of Bonum Therapeutics.

How many employees does Bonum Therapeutics have?

As of Mar 01, 2026, the latest employee count at Bonum Therapeutics is 10 - 49.

Is Bonum Therapeutics a funded company?

Bonum Therapeutics is a funded company, having raised a total of $120M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Nov 15, 2022.

When was the latest funding round of Bonum Therapeutics?

Bonum Therapeutics' latest funding was a $***** Series B round on Apr 03, 2026, with participation from 0 investor. Its primary sector is Oncology. In United States, the Oncology sector has seen $6.54B in funding in 2026 to date.

Where does Bonum Therapeutics rank among its competitors?

Bonum Therapeutics ranks 1033rd amongst 3434 active competitors, of which 1132 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Bonum Therapeutics?

Bonum Therapeutics' top competitors include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Among them, Immuneel secured the most recent funding round in June, 2026.

Bonum Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Bonum Therapeutics is a series B company based in Seattle (United States), founded in 2021 by John Mulligan. It operates as a Manufacturer of cytokine based drugs. Bonum Therapeutics has raised $120M in funding. The company has 3434 active competitors, including 1132 funded and 790 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Kite Pharma.

Company Details

Website: bonumtx.com
Social
Email ID: *****@bonumtx.com
Phone Number: +1 **********

Key Metrics

Founded Year

2021

Location

Seattle, United States

Stage

Series B

Total Funding

$120M in 2 rounds

Latest Funding Round

Series B, Apr 03, 2026, $*****

Investors

RiverVest Venture Partners & 5 more

Ranked

1033^rd among 3434 active competitors

Employee Count

10 - 49 as on Mar 01, 2026

Similar Companies

BeiGene & 622 more

View Bonum Therapeutics' full profile

Bonum Therapeutics is associated with 4 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Bonum M CIN: 40003940535 , Latvia, Active	Jul 19, 2007	€0 - €1M (As on Dec 31, 2024)	1 (As on Dec 31, 2022)	-
Bonum US CIN: 40103491406 , Latvia, Active	Dec 14, 2011	€0 - €1M (As on Dec 31, 2024)	1 (As on Dec 31, 2023)	-
Bonum Therapeutics, Inc. CIN: 872883314 , United States, Active	Dec 31, 1999	-	34 (As on Dec 31, 2024)	-
Bonum Therapeutics, Inc CIN: 87-2883314 , United States, Active	Dec 31, 2020	-	27 (As on Dec 31, 2022)	-

Bonum Therapeutics has raised a total funding of $120M over 2 rounds. Its first funding round was on Nov 15, 2022. Bonum Therapeutics has 6 institutional investors.

Here is the list of recent funding rounds of Bonum Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 03, 2026	3680436	Series B	9734383	1260429	8656259	6318349
Nov 15, 2022	6752175	Series A	3353337	5378055	1134269	Vivo Capital & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of Bonum Therapeutics's funding rounds and investors

The founders of Bonum Therapeutics is John Mulligan.

Here are the details of Bonum Therapeutics' key team members:

John Mulligan: Founder and CEO of Bonum Therapeutics.
Contact Info: 1 email address

View details of Bonum Therapeutics's Founder profiles and Board Members

Bonum Therapeutics' employee count trend

Bonum Therapeutics has 10 - 49 employees as of Mar 26. Here is Bonum Therapeutics's employee count trend over the years:

Employee count trend for Bonum Therapeutics

Uncover Bonum Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Bonum Therapeutics include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Here is the list of Top 10 competitors of Bonum Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	77/100
3rd	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Amgen Business Development ... & 10 others	76/100
4th	Attovia 2023, Fremont (United States), Public	Developer of antibody-based therapeutics for immune-mediated diseases and oncology	$255M	Deep Track Capital, Goldman Sachs Asset Management ... & 13 others	72/100
5th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	72/100
6th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	72/100
7th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
8th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
9th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
10th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	71/100
1033rd	Bonum Therapeutics 2021, Seattle (United States), Series B	Manufacturer of cytokine based drugs	$120M	RiverVest Venture Partners, Vivo Capital & 4 others	40/100